Relation of BMI and postmenopausal duration with antioxidant and anti-ınflammatory effects of raloxifene treatment in women with osteoporosis: a preliminary report

eyigor, sibel; SÖZMEN, Eser; Kirazlı, Yeşim; KARADENİZ, Muammer; Akçay, Yasemin; İLANBEY, BİLAL

Relation of BMI and postmenopausal duration with antioxidant and anti-ınflammatory effects of raloxifene treatment in women with osteoporosis: a preliminary report

Yasemin AKÇAY, (Ege Üniversitesi, Tıp Fakültesi, Biyokimya Anabilim Dalı, İzmir, Türkiye)

Sibel EYİGÖR, (Ege Üniversitesi, Tıp Fakültesi, Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı, İzmir, Türkiye)

Bilal İLANBEY, (Yozgat Devlet Hastanesi, Biyokimya Anabilim Dalı, Yozgat, Türkiye)

Muammer KARADENİZ, (Ege Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Endokrinoloji ve Metabolizma Bölümü, İzmir, Türkiye)

Yeşim KİRAZLI, (Ege Üniversitesi, Tıp Fakültesi, Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı, İzmir, Türkiye)

Eser SÖZMEN (Ege Üniversitesi, Tıp Fakültesi, Biyokimya Anabilim Dalı, İzmir, Türkiye)

Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi

4 3

Yıl: 2012 Cilt: 58 Sayı: 1 Sayfa Aralığı: 29 - 35 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Relation of BMI and postmenopausal duration with antioxidant and anti-ınflammatory effects of raloxifene treatment in women with osteoporosis: a preliminary report

Öz:

Amaç: Literatürde, raloksifen tedavisinin antioksidan ve antiinflamatuvar belirteçler üzerine olan etkileri ile ilişkili yeterli veri olmaması nedeniyle, çalışmamızda hem raloksifenin antioksidan ve antiinflamatuar etkilerini hem de osteoporozlu kadınlarda raloksifenin bu etkilerinin, vücut kütle indeksi (VKİ) ve menopoz süresi ile olan ilişkisini araştırdık. Gereç ve Yöntem: Osteoporozlu 14 kadın çalışmaya dahil edildi. 60 mg/gün olacak şekilde 6 ay boyunca raloksifen hidroklorid verildi. Oksidan/antioksidan durum eritrosit katalaz (e-CAT) ve paraoksonaz aktiviteleri, eritrosit tiyobarbitürik asid (e-TBARS), serum dien düzeyleri, total antioksidan aktivite (AOA), trolox eşedeğeri antioksidan aktivite (TEAC), plazma demir indirgeme kapasitesi (FRAP) ölçülerek belirlendi. Antiinflamatuvar etki ise tümor nekrozis factor (TNF-α), interlökin 6 (IL-6), İnterlökin 18 (IL-18), İnterlökin 10 (IL-10) ve adiponiktin düzeyleri ile belirlendi. Plazma sitokin düzeyleri (TNF-α, IL-6, IL-10, IL-18) ELISA kiti ile antioksidan parametreler spektrofotometrik olarak hem çalışmanın başında hemde sonunda ölçüldü. Bulgular: Tedavi sonrası IL-6 düzeyi anlamlı düşük, IL-10 ve PON1 düzeyi anlamlı yüksek olarak saptandı (p<0,05). Menopoz süresi 10 yıldan uzun ve VKİ<30 kg/m2 olan olgularda raloksifen tedavisi sonrası, IL-6 düzeyleri anlamlı düşük olarak saptandı (p<0,05). Sonuç: Raloksifen, osteoporozlu kadınlarda proinflamatuvar sitokin IL-6’yı anlamlı düşürürken, antiinflamatuvar sitokin IL-10’u ve antioksidan PON1’I anlamlı artırdı. Postmenapozal dönemde Raloksifenin hem antiinflamatuvar hem de antioksidan etkileri, VKİ ve menopoz süresi ile ilişkilidir. Türk Fiz Tıp Rehab Derg 2012;58:29-35.

Anahtar Kelime:

Konular: Rehabilitasyon

Osteoporozlu kadınlarda raloksifen tedavisinin antioksidan ve antiinflamatuvar etkilerininin VKİ ve menopoz süresi ile ilişkisi

Öz:

Objective: We have not identified any objective evidence in the literature about the effects of raloxifene treatment on the antioxidant and antiinflammatory markers. We investigated the antioxidant/anti-inflammatory effects of raloxifene and the association of its antioxidant/antiinflammatory effects with body mass index (BMI) and postmenopausal period in women with osteoporosis (OP). Materials and Methods: Fourteen postmenopausal women with OP were enrolled in this study. Raloxifene hydrochloride 60 mg/day was administered for 6 months. The oxidant/antioxidant state was evaluated by measuring erythrocyte catalase (e-CAT) and paraoxonase (PON1) activities, levels of thiobarbituric acid (e-TBARS), serum diene, total antioxidant activity (AOA), trolox equivalent antioxidant capacity (TEAC), ferric reducing ability of plasma (FRAP) and anti-inflammatory effects were assessed by measuring tumor necrosis factor (TNF)-α, Interleukin (IL-6), IL-18, IL-10 and adiponectin levels. Plasma cytokine (TNF-alpha, IL-6, IL-10, IL-18) levels were measured by ELISA kits and antioxidant parameters were determined by spectrophotometry. Serum levels of all parameters were measured at baseline and end of the study. Results: IL-6 level was significantly decreased but IL-10 and PON1 levels were significantly increased after the study treatment (p<0.05). Raloxifene treatment significantly decreased IL-6 levels when postmenopausal period was longer than 10 years and BMI was <30 kg/m2 (p<0.05). Conclusion: Raloxifene resulted in a significant decrease in pro-inflammatory cytokine IL-6 and significant increases in anti-inflammatory cytokine IL-10 and antioxidant PON1 levels in women with OP. BMI and postmenopausal period are both associated with anti-inflammatory and antioxidant effects of raloxifene in postmenopausal period. Turk J Phys Med Rehab 2012;58:29-35.

Anahtar Kelime:

Konular: Rehabilitasyon

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Horowitz MC. Cytokines and estrogen in bone: anti-osteoporotic effects. Science 1993;260:626-7.
2. Zheng SX, Vrindts Y, Lopez M, De Groote D, Zangerle PF, Collette J, et al. Increase in cytokine production (IL-1b, IL-6, TNF-alpha, but not IFN-c, GMCSF or LIF) by stimulated whole blood cells in postmenopausal osteoporosis. Maturitas 1997;26:63-71.
3. Wells G, Tugwell P, Shea B, Guyatt G, Peterson J, Zytaruk N, et al. Metaanalyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 2002;23:529-39.
4. Johnston CC Jr, Bjarnason NH, Cohen FJ, Shah A, Lindsay R, Mitlak BH, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipids in early postmenopausal women: three-year data from two double-blind, randomized, placebo controlled trials. Arch Intern Med 2000;160:3444-50.
5. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators mechanisms of action and application to clinical practice. N Engl J Med 2003;348:618-29.
6. Manolagas SC, Jilka RL. Mechanisms of disease: Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995;332:305-11.
7. Méndez-Dávila C, García-Moreno C, Turbì C, de la Piedra C. Effects of 17 beta-estradiol, tamoxifen and raloxifene on the protein and mRNA expression of interleukin-6, transforming growth Factor-beta1 and insulinlike growth factor-1 in pimary human osteoblast cultures. J Endocrinol Invest 2004;27:904-12.
8. Behl C, Skutella T, Lezoualc'h F, Post A, Widmann M, Newton CJ, et al. Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol Pharmacol 1997;51:535-41.
9. Garrett IR, Boyce BF, Oreffo RO, Bonewald L, Poser J, Mundy GR. Oxygenderived free radicals stimulate osteoclastic bone resorption in rodent bone in vitro and in vivo. J Clin Invest 1990;85:632-9.
10. Young IS, Woodside JV. Antioxidant in health and disease. J Clin Pathol 2001;54:176-86.
11. Berner HS, Lyngstadaas SP, Spahr A, Monjo M, Thommesen L, Drevon CA, et al. Adiponectin and its receptors are expressed in bone forming cells. Bone 2004;35:842-9.
12. Nakanishi S, Yamane K, Kamei N, Nojima H, Okubo M, Kohno N. Protective effect of adiponectin against oxidative stress in Japanese Americans: the association between adiponectin or leptin and urinary isoprostane. Metabolism 2005;54:194-9.
13. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993;94:646-50.
14. Sozmen EY, Sozmen B, Girgin FK, Delen Y, Azarsiz E, Erdener D, et al. Antioxidant enzymes and paraoxonase show co-activity in preserving LDL from oxidation. Clin Exp Med 2001;1:195-9.
15. Eckerson HW, Wyte C, La Du BN. The human serum paraoxonase/arylsterase polymorphism. Am J Hum Genet 1983;35;1126-38.
16. Sözmen EY, Tanyalçin T, Onat T, Kutay F, Erlaçin S. Ethanol induced oxidative stress and membrane injury in rats. Eur J Clin Chem Clin Biochem 1994;32:741-4.
17. Pulido R, Bravo L, Saura-Calixto F. Antioxidant activity of dietary polyphenols as determined by a modified FRAP assay. J Agric Food Chem 2000;48:3396-402.
18. RE R, Pellegrini N, Proteggente A, Pannala A, Yang M, Rice-Evans C. Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Radical Biol Med 1999;26:1231-7.
19. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999; 282:637-45.
20. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998;279:1445-51.
21. Walsh BW, Paul S, Wild RA, Dean RA, Tracy RP, Cox DA, et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2000;85:214-8.
22. Taranta A, Brama M, Teti A, De luca V, Scandurra R, Spera G, et al. The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 2002;30:368-76.
23. Ozmen B, Kirmaz C, Aydin K, Kafesciler SO, Guclu F, Hekimsoy Z. Influence of the selective estrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis. Eur Cytokine Netw 2007;18:148-53.
24. Mann V, Huber C, Kogianni G, Collins F, Noble B. The antioxidant effect of estrogen and Selective Estrogen Receptor Modulators in the inhibition of osteocyte apoptosis in vitro. Bone 2007;3:674-84.
25. Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams JS, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 1992;257:88-91.
26. Gür A, Denli A, Nas K, Cevik R, Karakoc M, Sarac AJ, et al. Possible pathogenetic role of new cytokines in postmenopausal osteoporosis and changes during calcitonin plus calcium therapy. Rheumatol Int 2002;22:194-8.
27. Dinarello CA, Moldawer LL. Proinflammatory and anti-inflammatory cytokines in rheumatoid arthritis. 2nd edition. Amgen 2000;23-75.
28. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000;96:1723-32.
29. Pacifici R. Cytokines, estrogen, and postmenopausal osteoporosis the second decade. Endocrinology 1998;139:2659-61.
30. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. N Engl J Med 1995;332:305-11.
31. Pratelli L, Cenni E, Granchi D, Tarabusi C, Ciapetti G, Pizzoferrato A. Cytokines of bone turnover in postmenopause and old age. Minerva Med 1999;90:101-9.
32. Sahin G, Ozturk C, Bagis S, Cimen O-B, Erdogan C. Correlation of serum cytokine levels with axial bone mineral density. Singapore Med J 2002;43:576-8.
33. Colacurci N, Fornaro F, Cobellis L, De Franciscis P, Torella M, Sepe E, et al.Raloxifene slows down the progression of intima-media thickness in postmenopausal women. Menopause 2007;14:879-84.
34. Albala C, Yáñez M, Devoto E, Sostin C, Zeballos L, Santos JL. Obesity as a protective factor for postmenopausal osteoporosis. Int J Obes Relat Metab Disord 1996;20:1027-32.
35. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000;11:327-32.
36. Hahn M, Conterato GM, Frizzo CP, Augusti PR, da Silva JC, Unfer TC, et al. Effects of bone disease and calcium supplementation on antioxidant enzymes in postmenopausal women. Clin Biochem 2008;41:69-74.
37. Lean JM, Jagger CJ, Kirstein B, Fuller K, Chambers TJ. Hydrogen peroxide essential for estrogen-deficiency bone loss and osteoclast formation. Endocrinology 2005;146:728-35.
38. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature 2000;408:239-47.

APA	Akçay Y, eyigor s, İLANBEY B, KARADENİZ M, Kirazlı Y, SÖZMEN E (2012). Relation of BMI and postmenopausal duration with antioxidant and anti-ınflammatory effects of raloxifene treatment in women with osteoporosis: a preliminary report. , 29 - 35.
Chicago	Akçay Yasemin,eyigor sibel,İLANBEY BİLAL,KARADENİZ Muammer,Kirazlı Yeşim,SÖZMEN Eser Relation of BMI and postmenopausal duration with antioxidant and anti-ınflammatory effects of raloxifene treatment in women with osteoporosis: a preliminary report. (2012): 29 - 35.
MLA	Akçay Yasemin,eyigor sibel,İLANBEY BİLAL,KARADENİZ Muammer,Kirazlı Yeşim,SÖZMEN Eser Relation of BMI and postmenopausal duration with antioxidant and anti-ınflammatory effects of raloxifene treatment in women with osteoporosis: a preliminary report. , 2012, ss.29 - 35.
AMA	Akçay Y,eyigor s,İLANBEY B,KARADENİZ M,Kirazlı Y,SÖZMEN E Relation of BMI and postmenopausal duration with antioxidant and anti-ınflammatory effects of raloxifene treatment in women with osteoporosis: a preliminary report. . 2012; 29 - 35.
Vancouver	Akçay Y,eyigor s,İLANBEY B,KARADENİZ M,Kirazlı Y,SÖZMEN E Relation of BMI and postmenopausal duration with antioxidant and anti-ınflammatory effects of raloxifene treatment in women with osteoporosis: a preliminary report. . 2012; 29 - 35.
IEEE	Akçay Y,eyigor s,İLANBEY B,KARADENİZ M,Kirazlı Y,SÖZMEN E "Relation of BMI and postmenopausal duration with antioxidant and anti-ınflammatory effects of raloxifene treatment in women with osteoporosis: a preliminary report." , ss.29 - 35, 2012.
ISNAD	Akçay, Yasemin vd. "Relation of BMI and postmenopausal duration with antioxidant and anti-ınflammatory effects of raloxifene treatment in women with osteoporosis: a preliminary report". (2012), 29-35.

APA	Akçay Y, eyigor s, İLANBEY B, KARADENİZ M, Kirazlı Y, SÖZMEN E (2012). Relation of BMI and postmenopausal duration with antioxidant and anti-ınflammatory effects of raloxifene treatment in women with osteoporosis: a preliminary report. Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi, 58(1), 29 - 35.
Chicago	Akçay Yasemin,eyigor sibel,İLANBEY BİLAL,KARADENİZ Muammer,Kirazlı Yeşim,SÖZMEN Eser Relation of BMI and postmenopausal duration with antioxidant and anti-ınflammatory effects of raloxifene treatment in women with osteoporosis: a preliminary report. Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi 58, no.1 (2012): 29 - 35.
MLA	Akçay Yasemin,eyigor sibel,İLANBEY BİLAL,KARADENİZ Muammer,Kirazlı Yeşim,SÖZMEN Eser Relation of BMI and postmenopausal duration with antioxidant and anti-ınflammatory effects of raloxifene treatment in women with osteoporosis: a preliminary report. Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi, vol.58, no.1, 2012, ss.29 - 35.
AMA	Akçay Y,eyigor s,İLANBEY B,KARADENİZ M,Kirazlı Y,SÖZMEN E Relation of BMI and postmenopausal duration with antioxidant and anti-ınflammatory effects of raloxifene treatment in women with osteoporosis: a preliminary report. Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi. 2012; 58(1): 29 - 35.
Vancouver	Akçay Y,eyigor s,İLANBEY B,KARADENİZ M,Kirazlı Y,SÖZMEN E Relation of BMI and postmenopausal duration with antioxidant and anti-ınflammatory effects of raloxifene treatment in women with osteoporosis: a preliminary report. Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi. 2012; 58(1): 29 - 35.
IEEE	Akçay Y,eyigor s,İLANBEY B,KARADENİZ M,Kirazlı Y,SÖZMEN E "Relation of BMI and postmenopausal duration with antioxidant and anti-ınflammatory effects of raloxifene treatment in women with osteoporosis: a preliminary report." Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi, 58, ss.29 - 35, 2012.
ISNAD	Akçay, Yasemin vd. "Relation of BMI and postmenopausal duration with antioxidant and anti-ınflammatory effects of raloxifene treatment in women with osteoporosis: a preliminary report". Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi 58/1 (2012), 29-35.